Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) issued its earnings results on Monday. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.29), FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Bicara says its pivotal FORTIFY-HN01 trial is on track for substantial enrollment by year-end, with an interim analysis planned in mid‑2027 to support potential accelerated approval of FICERA.
• Peer‑reviewed phase I‑B data (1,500 mg weekly + pembrolizumab) published in JCO showed deep, durable activity (median DOR 21.7 months; median OS 21.3 months) and the company will present 3‑year follow‑up across cohorts at ASCO.
• Bicara plans an alternative‑dosing randomized study (≈150–200 patients) starting in 3Q testing a 12‑week 1,500 mg weekly induction then either continued weekly or 2,250 mg every‑3‑weeks maintenance, with PFS as the primary endpoint to enable a more practical commercial regimen.
• Financially, the company ended Q1 with about $539.8M in cash and raised $161.8M (net) in February, providing runway into H1 2029, while warning operating expenses will rise as it funds the pivotal trial and builds commercial infrastructure.
• Management changes and commercial hires—Bill Schelman promoted to CMO and Alex Kharazi hired as CCO—signal preparations to transition from clinical stage to a commercial organization ahead of a potential launch.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX traded down $0.75 during trading hours on Wednesday, hitting $21.63. 75,478 shares of the stock were exchanged, compared to its average volume of 507,452. Bicara Therapeutics has a one year low of $7.80 and a one year high of $24.25. The company’s 50 day moving average is $20.86 and its 200 day moving average is $18.12. The firm has a market capitalization of $1.42 billion, a P/E ratio of -7.82 and a beta of -0.57.

Analysts Set New Price Targets

Several brokerages recently weighed in on BCAX. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Citigroup began coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. Bank of America began coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target for the company. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.27.

Insider Activity

In other news, COO Ryan Cohlhepp sold 17,392 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the sale, the chief operating officer directly owned 205,141 shares of the company’s stock, valued at approximately $3,725,360.56. This trade represents a 7.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the completion of the transaction, the chief executive officer owned 339,392 shares in the company, valued at $6,506,144.64. The trade was a 9.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 174,310 shares of company stock worth $3,459,283.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently added to or reduced their stakes in BCAX. AQR Capital Management LLC acquired a new stake in Bicara Therapeutics in the 1st quarter valued at approximately $248,000. Woodline Partners LP lifted its holdings in shares of Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after buying an additional 72,998 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after acquiring an additional 180,833 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Bicara Therapeutics by 26.0% in the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after acquiring an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.